These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Protease inhibitors: current status and future prospects. Leung D; Abbenante G; Fairlie DP J Med Chem; 2000 Feb; 43(3):305-41. PubMed ID: 10669559 [No Abstract] [Full Text] [Related]
3. Proteases and their inhibitors in human brain tumours: a review. Rooprai HK; McCormick D Anticancer Res; 1997; 17(6B):4151-62. PubMed ID: 9428349 [TBL] [Abstract][Full Text] [Related]
4. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus. Tsantrizos YS Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464 [TBL] [Abstract][Full Text] [Related]
5. [Proteases in malignant tumors. Their significance for pathogenesis and possible therapeutic consequences]. Fröhlich E Dtsch Med Wochenschr; 2004 Feb; 129(8):391-5. PubMed ID: 14961448 [No Abstract] [Full Text] [Related]
6. [A study of the complex of proteolytic enzymes and their protein inhibitors in embryogenesis of the silkworm]. Iarygin DV; Klunova SM; Filippovich IB Ontogenez; 2001; 32(4):269-76. PubMed ID: 11573423 [TBL] [Abstract][Full Text] [Related]
7. Selective inhibitors of picornavirus replication. De Palma AM; Vliegen I; De Clercq E; Neyts J Med Res Rev; 2008 Nov; 28(6):823-84. PubMed ID: 18381747 [TBL] [Abstract][Full Text] [Related]
9. [A comparative study of aspartyl and cysteine proteinases and their inhibitors in human B- and T-cell leukemias]. Gureeva TA; Golubeva NV; Lubkova ON; Lokshina LA Vopr Med Khim; 1994; 40(3):6-8. PubMed ID: 8079445 [TBL] [Abstract][Full Text] [Related]
10. Synthetic protease inhibitors: promising compounds to arrest pathobiologic processes. Roose JP; Van Noorden CJ J Lab Clin Med; 1995 Apr; 125(4):433-41. PubMed ID: 7706897 [No Abstract] [Full Text] [Related]
11. Viral protease inhibitors. Anderson J; Schiffer C; Lee SK; Swanstrom R Handb Exp Pharmacol; 2009; 189(189):85-110. PubMed ID: 19048198 [TBL] [Abstract][Full Text] [Related]
12. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases. Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323 [TBL] [Abstract][Full Text] [Related]
13. Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach. Melino S; Paci M FEBS J; 2007 Jun; 274(12):2986-3002. PubMed ID: 17509079 [TBL] [Abstract][Full Text] [Related]
14. The secreted aspartic proteinases as a new target in the therapy of candidiasis. Bein M; Schaller M; Korting HC Curr Drug Targets; 2002 Oct; 3(5):351-7. PubMed ID: 12182226 [TBL] [Abstract][Full Text] [Related]
15. Non-covalent inhibitors of rhinovirus 3C protease. Baxter A; Chambers M; Edfeldt F; Edman K; Freeman A; Johansson C; King S; Morley A; Petersen J; Rawlins P; Spadola L; Thong B; Van de Poël H; Williams N Bioorg Med Chem Lett; 2011 Jan; 21(2):777-80. PubMed ID: 21183345 [TBL] [Abstract][Full Text] [Related]
16. Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents. Supuran CT; Casini A; Scozzafava A Med Res Rev; 2003 Sep; 23(5):535-58. PubMed ID: 12789686 [TBL] [Abstract][Full Text] [Related]
17. The picornaviral 3C proteinases: cysteine nucleophiles in serine proteinase folds. Malcolm BA Protein Sci; 1995 Aug; 4(8):1439-45. PubMed ID: 8520469 [TBL] [Abstract][Full Text] [Related]
18. Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity. Stoermer MJ; Chappell KJ; Liebscher S; Jensen CM; Gan CH; Gupta PK; Xu WJ; Young PR; Fairlie DP J Med Chem; 2008 Sep; 51(18):5714-21. PubMed ID: 18729351 [TBL] [Abstract][Full Text] [Related]